Caladrius Biosciences Inc. (NASDAQ:CLBS) went down by -3.78% from its latest closing price compared to the recent 1-year high of $4.89. The company’s stock price has collected -3.78% of loss in the last five trading sessions. Press Release reported on 03/08/21 that Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease
Is It Worth Investing in Caladrius Biosciences Inc. (NASDAQ :CLBS) Right Now?
Plus, the 36-month beta value for CLBS is at 1.12. Opinions of the stock are interesting as 2 analysts out of 3 who provided ratings for Caladrius Biosciences Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $10.00. CLBS currently public float of 46.06M and currently shorts hold a 3.89% ratio of that float. Today, the average trading volume of CLBS was 6.64M shares.
CLBS’s Market Performance
CLBS stocks went down by -3.78% for the week, with a monthly drop of -0.56% and a quarterly performance of 23.61%, while its annual performance rate touched 1.14%. The volatility ratio for the week stands at 6.28% while the volatility levels for the past 30 days are set at 7.54% for Caladrius Biosciences Inc.. The simple moving average for the period of the last 20 days is -10.64% for CLBS stocks with a simple moving average of -6.19% for the last 200 days.
Analysts’ Opinion of CLBS
H.C. Wainwright, on the other hand, stated in their research note that they expect to see CLBS reach a price target of $18.50. The rating they have provided for CLBS stocks is “Buy” according to the report published on November 20th, 2018.
Chardan Capital Markets gave a rating of “Buy” to CLBS, setting the target price at $6.50 in the report published on August 23rd of the previous year.
CLBS Trading at -14.69% from the 50-Day Moving Average
After a stumble in the market that brought CLBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.60% of loss for the given period.
Volatility was left at 7.54%, however, over the last 30 days, the volatility rate increased by 6.28%, as shares sank -2.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.52% lower at present.
During the last 5 trading sessions, CLBS fell by -3.78%, which changed the moving average for the period of 200-days by -2.73% in comparison to the 20-day moving average, which settled at $1.9895. In addition, Caladrius Biosciences Inc. saw 24.48% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at CLBS starting from Davidson Michael H., who purchase 55,525 shares at the price of $1.80 back on Sep 09. After this action, Davidson Michael H. now owns 106,588 shares of Caladrius Biosciences Inc., valued at $99,945 using the latest closing price.
Stock Fundamentals for CLBS
The total capital return value is set at -76.27, while invested capital returns managed to touch -30.08. Equity return is now at value -26.90, with -23.70 for asset returns.
Based on Caladrius Biosciences Inc. (CLBS), the company’s capital structure generated 1.92 points at debt to equity in total, while total debt to capital is 1.88. Total debt to assets is 1.73, with long-term debt to equity ratio resting at 0.78. Finally, the long-term debt to capital ratio is 0.77.
The liquidity ratio also appears to be rather interesting for investors as it stands at 10.08.